| Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients S Gingele, TL Jacobus, FF Konen, MW Hümmert, KW Sühs, ... Cells 8 (1), 12, 2018 | 130 | 2018 |
| Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy—review of the literature and future outlook N Möhn, G Beutel, R Gutzmer, P Ivanyi, I Satzger, T Skripuletz Journal of Clinical Medicine 8 (11), 1777, 2019 | 126 | 2019 |
| Frequency and characterization of movement disorders in anti-IgLON5 disease C Gaig, Y Compta, A Heidbreder, MJ Marti, MJ Titulaer, Y Crijnen, B Högl, ... Neurology 97 (14), e1367-e1381, 2021 | 77 | 2021 |
| Experience in multiple sclerosis patients with COVID-19 and disease-modifying therapies: a review of 873 published cases N Möhn, FF Konen, R Pul, C Kleinschnitz, H Prüss, T Witte, M Stangel, ... Journal of clinical medicine 9 (12), 4067, 2020 | 76 | 2020 |
| Interleukin 17, produced by γδ T cells, contributes to hepatic inflammation in a mouse model of biliary atresia and is increased in livers of patients C Klemann, A Schröder, A Dreier, N Möhn, S Dippel, T Winterberg, ... Gastroenterology 150 (1), 229-241. e5, 2016 | 64 | 2016 |
| Leptomeningeal metastasis: the role of cerebrospinal fluid diagnostics L Bönig, N Möhn, J Ahlbrecht, U Wurster, P Raab, W Puppe, KW Sühs, ... Frontiers in neurology 10, 839, 2019 | 54 | 2019 |
| Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome K Stahl, BMW Schmidt, MM Hoeper, T Skripuletz, N Möhn, G Beutel, ... Journal of Critical Care 57, 124-129, 2020 | 34 | 2020 |
| Allogeneic BK virus-specific T-cell treatment in 2 patients with progressive multifocal leukoencephalopathy F Hopfner, N Möhn, B Eiz-Vesper, B Maecker-Kolhoff, J Gottlieb, ... Neurology: Neuroimmunology & Neuroinflammation 8 (4), e1020, 2021 | 28 | 2021 |
| 18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma T Derlin, C Schultze-Florey, RA Werner, N Möhn, T Skripuletz, S David, ... Annals of Nuclear Medicine 35, 132-138, 2021 | 28 | 2021 |
| Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF N Möhn, S Pfeuffer, T Ruck, CC Gross, T Skripuletz, L Klotz, H Wiendl, ... Neurology: Neuroimmunology & Neuroinflammation 7 (2), e654, 2019 | 28 | 2019 |
| Intrathecal antibody production against epstein-barr, herpes simplex, and other neurotropic viruses in autoimmune encephalitis P Schwenkenbecher, T Skripuletz, P Lange, M Dürr, FF Konen, N Möhn, ... Neurology: Neuroimmunology & Neuroinflammation 8 (6), e1062, 2021 | 27 | 2021 |
| Implications of COVID-19 outbreak on immune therapies in multiple sclerosis patients—lessons learned from SARS and MERS N Möhn, R Pul, C Kleinschnitz, H Prüss, T Witte, M Stangel, T Skripuletz Frontiers in immunology 11, 1059, 2020 | 23 | 2020 |
| Treatment of autoimmunity: the impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders FF Konen, N Möhn, T Witte, M Schefzyk, M Wiestler, S Lovric, K Hufendiek, ... Autoimmunity Reviews 22 (5), 103312, 2023 | 22 | 2023 |
| Innovative therapeutic concepts of progressive multifocal leukoencephalopathy N Möhn, L Grote-Levi, F Hopfner, B Eiz-Vesper, B Maecker-Kolhoff, ... Journal of Neurology 269 (5), 2403-2413, 2022 | 20 | 2022 |
| Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse N Möhn, F Saker, V Bonda, G Respondek, M Bachmann, M Stoll, ... Journal of Neurology 267, 2803-2805, 2020 | 20 | 2020 |
| Acute progressive neuropathy–myositis–myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma N Möhn, KW Sühs, S Gingele, Y Angela, M Stangel, R Gutzmer, I Satzger, ... Melanoma Research 29 (4), 435-440, 2019 | 20 | 2019 |
| Therapy with cladribine is efficient and safe in patients previously treated with natalizumab N Möhn, T Skripuletz, KW Sühs, S Menck, E Voß, M Stangel Therapeutic Advances in Neurological Disorders 12, 1756286419887596, 2019 | 18 | 2019 |
| Cerebrospinal fluid parameters in antisense oligonucleotide-treated adult 5q-spinal muscular atrophy patients LH Müschen, A Osmanovic, C Binz, KF Jendretzky, G Ranxha, P Bronzlik, ... Brain Sciences 11 (3), 296, 2021 | 17 | 2021 |
| PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy N Möhn, MP Wattjes, O Adams, S Nay, D Tkachenko, F Salge, J Heine, ... Therapeutic Advances in Neurological Disorders 14, 1756286421993684, 2021 | 12 | 2021 |
| Neurological management and work-up of neurotoxicity associated with CAR T cell therapy N Möhn, V Bonda, L Grote-Levi, V Panagiota, T Fröhlich, ... Neurological Research and Practice 4, 1-10, 2022 | 11 | 2022 |
